RCAC,Revelstone Capital Acquisition Corp. | Financials

Financials

RCAC

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

Revelstone Capital Acquisition Corp.RCAC

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

Revelstone Capital Acquisition Corp. does not have significant operations.

It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the consumer, media, and/or technology markets.

Revelstone Capital Acquisition Corp. was incorporated in 2021 and is based in Irvine, California.

Latest News >

XTL Biopharmaceuticals to Change ADS Ratio

Mar 20, 2026

04:34 PM EDT, 03/20/2026 (MT Newswires) -- XTL Biopharmaceuticals (XTLB) said late Friday it plans to change the ratio of its American Depositary Shares to 1 ADS to 400 shares from 1 ADS to 100 shares, effective March 25. The ratio change will have the same effect as a 1-for-4 reverse ADS split for its ADS holders, the company said....

Super Micro Computer Announces Resignation of Board Member Yih-Shyan "Wally" Liaw

Mar 20, 2026

DeAnna Luna Appointed Acting Chief Compliance Officer SAN JOSE, Calif., March 20, 2026 /PRNewswire/ -- Super Micro Computer, Inc. ( SMCI ) (Supermicro or the Company) today announced that Yih-Shyan Wally Liaw (Mr. Liaw) has resigned from the Company's Board of Directors, effective immediately. Following Mr. Liaw's resignation, the Company's Board comprises eight directors. There are no changes to the...

Mohawk Industries Insider Sold Shares Worth $581,950, According to a Recent SEC Filing

Mar 20, 2026

04:43 PM EDT, 03/20/2026 (MT Newswires) -- Suzanne L Helen, Possible Member of Group, on March 19, 2026, sold 6,000 shares in Mohawk Industries ( MHK ) for $581,950. Following the Form 4 filing with the SEC, Helen has control over a total of 192,539 common shares of the company, with 192,539 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/851968/000127137326000004/xslF345X05/primary_doc.xml ...

Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)

Mar 20, 2026

In the U.S., FDA approval establishes Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD) as the first immunotherapy combination approved for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin Lymphoma (cHL) With approval in the EU, Opdivo in combination with brentuximab vedotin is now the first immunotherapy combination approved...